Arcus Biosciences, Inc.

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 26,350 shares of the Company's common stock at an exercise price per share of $29.06, which was the.

Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in September: Citi's 2026 Biotech Back to School Conference Date: Wednesday, September 9th, 2026 Location: New York, NY Format: Fireside chat &amp.

BlackRock Inc. bought a new stake in Arcus Biosciences, Inc. (NYSE: RCUS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 16,416,249 shares of the company's stock, valued at approximately $506,113,000. BlackRock Inc. owned 13.05% of Arcus Biosciences at